AU678971B2 - Compositions and methods for vaccination against coronaviruses - Google Patents

Compositions and methods for vaccination against coronaviruses

Info

Publication number
AU678971B2
AU678971B2 AU42410/93A AU4241093A AU678971B2 AU 678971 B2 AU678971 B2 AU 678971B2 AU 42410/93 A AU42410/93 A AU 42410/93A AU 4241093 A AU4241093 A AU 4241093A AU 678971 B2 AU678971 B2 AU 678971B2
Authority
AU
Australia
Prior art keywords
compositions
methods
vaccination against
against coronaviruses
coronaviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU42410/93A
Other versions
AU4241093A (en
Inventor
Elaine V Jones
Sharon Klepfer
Timothy J Miller
Albert Paul Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU4241093A publication Critical patent/AU4241093A/en
Application granted granted Critical
Publication of AU678971B2 publication Critical patent/AU678971B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU42410/93A 1992-05-08 1993-05-07 Compositions and methods for vaccination against coronaviruses Ceased AU678971B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US822171 1992-01-16
US88217192A 1992-05-08 1992-05-08
PCT/US1993/004384 WO1993023422A1 (en) 1992-05-08 1993-05-07 Compositions and methods for vaccination against coronaviruses

Publications (2)

Publication Number Publication Date
AU4241093A AU4241093A (en) 1993-12-13
AU678971B2 true AU678971B2 (en) 1997-06-19

Family

ID=25380027

Family Applications (2)

Application Number Title Priority Date Filing Date
AU42404/93A Ceased AU678970B2 (en) 1992-05-08 1993-05-07 Universal coronavirus vaccine
AU42410/93A Ceased AU678971B2 (en) 1992-05-08 1993-05-07 Compositions and methods for vaccination against coronaviruses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU42404/93A Ceased AU678970B2 (en) 1992-05-08 1993-05-07 Universal coronavirus vaccine

Country Status (5)

Country Link
EP (2) EP0640096A4 (en)
JP (2) JPH08501931A (en)
AU (2) AU678970B2 (en)
CA (2) CA2134898A1 (en)
WO (2) WO1993023421A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034298A (en) * 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5612487A (en) * 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
WO1993023421A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Universal coronavirus vaccine
JP3245169B2 (en) * 1992-05-08 2002-01-07 ファイザー・インコーポレイテッド Canine coronavirus S gene and uses thereof
AU721367B2 (en) * 1993-02-26 2000-06-29 Wyeth Holdings Corporation Canine coronavirus vaccine from feline enteric coronavirus
EP0612532A3 (en) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Canine coronavirus vaccine from feline enteric coronavirus
GB2282601B (en) * 1993-09-16 1998-04-15 Solvay Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
FR2724385B1 (en) * 1994-08-29 1996-12-13 Rhone Merieux FELINE INFECTIOUS PERITONITIS VACCINE.
WO1997010347A1 (en) * 1995-09-15 1997-03-20 Howard John A Expression cassettes and methods for delivery of animal vaccines
WO1998027433A1 (en) * 1996-12-18 1998-06-25 Engene Biotechnologies, Inc A specific diagnostic for antibodies to feline infectious peritonitis virus
AU1408499A (en) * 1997-11-14 1999-06-07 Thomas P. Brown Compositions and methods to prevent turkey enteritis
WO2001009290A2 (en) * 1999-07-30 2001-02-08 Laboratorio Avi-Mex, S.A. De C.V. Avian infectious bronchitis virus serotype
FR2828405B1 (en) * 2001-08-09 2005-06-24 Virbac Sa ANTI-CORONAVIRUS VACCINE
WO2005010034A1 (en) * 2003-07-21 2005-02-03 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Soluble fragments of the sars-cov spike glycoprotein
US7605135B2 (en) * 2003-11-10 2009-10-20 The University Of Hong Kong Baicalin as a treatment for SARS infection
ITMI20111182A1 (en) * 2011-06-28 2012-12-29 Canio Buonavoglia VACCINE FOR CORONAVIRUS CANINO
WO2015143335A1 (en) * 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
CN113248576A (en) * 2020-02-12 2021-08-13 北京科兴中维生物技术有限公司 Nucleic acid vaccine for coronavirus and preparation method thereof
WO2022020815A1 (en) * 2020-07-24 2022-01-27 Soligenix, Inc. Antibody/adjuvant compositions and methods of immune response generation against coronaviruses
CN113072626B (en) * 2021-04-25 2023-05-05 龙岩学院 Cat coronavirus S recombinant protein and preparation method thereof
CN113238048B (en) * 2021-05-11 2024-03-15 抗码(苏州)生物科技有限公司 Diagnostic markers and their use in differentiating between new coronavirus infection and new coronavirus inactivated vaccination
CN113861278B (en) * 2021-06-18 2022-08-05 国药中生生物技术研究院有限公司 Novel recombinant coronavirus RBD trimer protein vaccine capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
CN114478716B (en) * 2021-12-28 2024-05-28 梅州市人民医院(梅州市医学科学院) Polypeptide combination and application thereof in novel coronavirus antibody detection
CN114773487A (en) * 2022-05-31 2022-07-22 湖南大学 Influenza virus and novel coronavirus fusion recombinant protein vaccine immunogen and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264979A1 (en) * 1986-09-05 1988-04-27 Duphar International Research B.V New antigenically active proteins and peptides, and feline infectious peritonitis virus (FIPV) vaccines
CA2005291C (en) * 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
WO1991002752A1 (en) * 1989-08-22 1991-03-07 Veterinary Infectious Disease Organization Bovine coronavirus polypeptides and vaccines
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
JP3245169B2 (en) * 1992-05-08 2002-01-07 ファイザー・インコーポレイテッド Canine coronavirus S gene and uses thereof
WO1993023421A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Universal coronavirus vaccine

Also Published As

Publication number Publication date
EP0640096A4 (en) 1997-01-15
EP0640097A1 (en) 1995-03-01
AU4241093A (en) 1993-12-13
EP0640097A4 (en) 1997-01-15
JPH08501931A (en) 1996-03-05
AU4240493A (en) 1993-12-13
CA2135201A1 (en) 1993-11-25
EP0640096A1 (en) 1995-03-01
JPH07508176A (en) 1995-09-14
WO1993023421A1 (en) 1993-11-25
CA2134898A1 (en) 1993-11-25
AU678970B2 (en) 1997-06-19
WO1993023422A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
AU678971B2 (en) Compositions and methods for vaccination against coronaviruses
AU3201093A (en) Dental composition and method
EP0650370A4 (en) Methods and compositions for targeting specific tissue.
AU3691793A (en) Gas well treatment compositions and methods
AU4534593A (en) Compositions and methods for enhanced drug delivery
AU7270091A (en) Method and composition for coiontophoresis
AU7564694A (en) Erection-inducing methods and compositions
AU7323294A (en) Perfluoroelastomeric compositions and methods
AU4225093A (en) Methods and pharmaceutical compositions for treating episodic heartburn
AU3249793A (en) Compositions and methods for modulating beta -amyloid
AU3802493A (en) Surgical endoclip
AU2514592A (en) Methods and compositions for modulating g protein action
AU1086392A (en) Procedure for hydrolyzing keratin
AU6298894A (en) Compositions and methods for promoting hair growth
AU5852794A (en) Sterilization devices, sporidical compositions, sterilization methods, and devices for reducing surface tension
AU6847894A (en) Method for the improvement of wound healing and compositions therefor
AU5544194A (en) Aldehyde scavenging compositions and methods relating thereto
AU6285194A (en) Stabilised pharmaceutical compositions and methods for preparing same
AU3635693A (en) 1,4-dialkylpiperazine derivatives, method for obtaining them and pharmaceutical compositions containing them
AU2821295A (en) Compositions and methods for the treatment of tumors
AU4489693A (en) Apparatus and methods for improved construction
AU7008494A (en) Methods and compositions for (salmonella)-based vaccines
AU4468093A (en) Composition and methods for the generation of bone
AU4840893A (en) Surgical apparatus
AU3011692A (en) Horseshoes and method for their preparation

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired